Guardant Health, which makes non-invasive blood-based cancer diagnostics tests, raised $238 million by offering 12.5 million shares at $19, above the range of $15 to $17. Guardant Health plans to list on the Nasdaq under the symbol GH. J.P. Morgan and BofA Merrill Lynch acted as lead managers on the deal.
